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SUMMARY
Dopamine, a naturally occurring catecholamine is extensively used in the intensive
care setting. Dopamine exerts a complicated influence on the cardiovascular and renal
system. This is due to the fact that dopamine stimulates different types of adrenergic
receptors: not only o- and B-adrenergic but also specific dopamine receptors. And
each of these receptors can be divided in two subtypes according to the effects
exerted by their stimulation. Dopamine can be applied for various indications depend-
ing on the given dose. This is due to the amount of stimulation and the change of
balance of these receptor effects for different doses. In doses of 1-4 pglkglmin,
nicknamed "renal dose", the predominant effect of dopamine is a marked increase of
renal plasma flow, glomerular filtration rate and sodium excretion. This is mainly
caused by stimulation of dopamine-receptors. In doses of 4-10 pgkglmin dopamine
exerts positive inotropic effects, primarily as a result of B-(1)-receptor stimulation. ln
doses of above 10 pgkglmin dopamine induces vasoconstriction and positive chronot-
ropism as a result of predominant a-adrenergic and B-adrenergic effects, respectively.
The scheme sketched above for different doses of dopamine is in fact a simplification
of a balance of counteracting effects of stimulation of different receptors by dopa-
mine.
Dopamine receptors are present at various sites of the body, not only in the Central
Nervous System (CNS), but also outside the CNS, the so called peripheral dopamine
receptors. These receptors are divided in two types: postsynaptic DAl, and (presynap-
tic) DA2 receptors. DA1 receptors are located in blood vessels and in the proximal
tubule of the kidney. Stimulation induces vasodilation and natriuresis. The DA2
receptors are situated prejunctionally on sympathetic nerve terminals and in the
adrenal gland. Stimulation of DA2-dopamine receptors results in inhibition of norepi-
nephrine release and inhibition of aldosterone secretion.
More widespread use of dopamine (agonists) is limited because of a lack of oral
availability. [n recent years some orally active dopamine agonists have become avail-
able for clinical studies. This thesis describes rcnal and neurDhumofa) effecti of two
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dilerentdopamrne-receptors. Aspects of intracellular transduction mechanfsms after
stimulation of dopamine receptors are discussed. In earlier studies some evidence was
found that abnormalities of endogenous dopamine release or dopamine receptors are
present in hypertension - and possibly heart failure. Currently, animal studies suggest
post-receptoi defects of dopamine-receptors in animal models for essential hyperten-
sion.
with diverse techniques dopamine-receptors can now be localized. The presence of
DAl-receptors in different vascular beds and the renal proximal tubule is now estab-
lished. DA2-receptors are unequivocally recognized prejunctionally on sympathetic
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nerve terminals and in the adrenal gland. However, with regard to the ganglionic
dopamine-receptors, the question of receptor subtypes involved, still needs to be
resolved.
Subsequently, fenoldopam, a selective DA1-receptor agonist, and ibopamine, an
aselective dopamine agonist with o- and B-adrenergic activity are discussed. Short
attention is given to dopexamine, an aselective dopamine- and f32-agonist, which is for
intravenous use only.
Fenoldopam induces vasodilatation with a fall in systemic vascular resistance and
increase of cardiac output, a pronounced increase of renal blood flow and natriuresis,
the latter being (partially) induced by stimulation of proximal tubular DAl-receptors.
The clinical applications therefore appear to be hypertension and especially hyperten-
sive emergencies, and heart failure.
Ibopamine, a prodrug, is the di-isobutyryl ester of methyl-dopamine (epinine) and is
de-esterified to epinine after oral administration. Epinine, stimulates o-, B-adrenergic
and DA1- and DA2-dopamine receptors. Oral administration of ibopamine in normal
man has been reported to result in an increase of sodium excretion and creatinine
clearance, without changes in heart rate and blood pressure. In patients with conges-
tive heart failure, ibopamine improves the hemodynamic parameters with an increase
of cardiac index, and a fall of systemic- and pulmonary vascular resistance.
Additionally, the effects of ibopamine on plasma norepinephrine are discussed.
Considering the lack of effect on blood pressure, ibopamine plays no role in the
treatment of hypertension, in contrast to fenoldopam.
Finally, future perspectives for clinical applications of dopamine agonists, are dis-
cussed. A diuretic and natriuretic drug, which increases renal blood flow, but also
induces some degree of systemic vasodilatation, appears to be a promising addition to
the current therapeutic tools. One might expect that ibopamine, fenoldopam and
dopexamine can play an additional role in the treatment of heart failure. Several
studies indicate that fenoldopam possesses a favorable profile in the treatment of
severe hypertension, compared to nitroprusside.
Chapter 2 describes the renal and neurohumoral effects of i.v. fenoldopam in ascend-
ing doses, in healthy volunteers. The influence of the aselective dopamine antagonist
metoclopramide on fenoldopam-induced changes was also investigated. During
fenoldopam infusion the diastolic blood pressure fell slightly, with a rise in heart rate.
Renal blood flow increased markedly, while the GFR remained unchanged. These
effects of fenoldopam were not altered by metoclopramide. Fenoldopam induced an
increase of sodium excretion, which was abolished by metoclopramide. A pronounced
rise of PRA during fenoldopam infusion was found, which was blunted by metoclopra-
mide. This rise of PRA is probably not only a compensatory reflex to the fall in blood
pressure due to fenoldopam, but also a result of direct stimulation of juxtaglomerular
cells. Metoclopramide induced a marked increase of aldosterone, sustained, but
blunted during subsequent fenoldopam infusion, suggesting a DAl-receptor medjated
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metoclopramide no changes of norepinephrine occurred. We concluded that fenol-
dopam induces systemic and renal vasodilation but only moderate natriuresis. These
effects are counteracted by activation of the Renin-Angiotensin-Aldosterone-System
(RAAS) as evidenced by a rise of PRA, and subsequently aldosterone, and the
sympathetic nervous system (SNS), reflected in the rise of norepinephrine. [n previous
studies with dopamine no such effects on RAAS and SNS have been observed.
Whether the counteracting mechanisms will largely obscure the primary effects of
fenoldopam, remains subject for further studies.
lbopamine as an aselective dopamine agonist may compare favorably with fenoldopam
if the DA2-receptor stimulation by ibopamine would limit the RAAS and SNS activa-
tion following DAI-receptor stimulation. Therefore, after the fenoldopam study, we
investigated the renal and neurohumoral effects of oral ibopamine in a comparable
study setting, again in normal man. Although numerous studies with ibopamine have
been completed, no studies addressing simultaneously the GFR, renal blood flow and
sodium excretion had been performed. Chapter 3 describes the effects of ibopamine
on renal function and neurohumoral parameters in healthy volunteers. Ibopamine
induced a moderate and transient increase of GFR, which was abolished by metoclclp-
ramide. No changes in renal blood flow were observed. This may be the consequence
of simultaneous DA1- and o-receptor stimulation or only weak DAl-receptor stimula-
tion. Ibopamine induced a modest but significant increase of absolute and fractional
sodium excretion. The fall in sodium excretion due to metoclopramide was not re-
versed by ibopamine. Ibopamine did not cause any changes in PRA, aldosterone and
norepinephrine. The metoclopramide-induced rise of aldosterone was markedly
blunted by ibopamine. We concluded that ibopamine induces a transient increase of
GFR and natriuresis. The latter is not caused by renal hemodynamic effects, but
probably by direct stimulation of tubular DA1-receptors in the kidney.
Lithium is commonly used as a marker of proximal tubule function. In a recent study,
evidence was provided that lithium interacts with dopamine receptors at the level of
the renal tubule: the natriuresis induced by the dopamine prodrug gludopa, was
abolished by lithium. In chapter 4 the lack of effect of lithium on the renal - natriuret-
ic - response to fenoldopam in normal man is described. In this study renal vasodila-
tion, sodium excretion, PRA and aldosterone were assessed. The increase of PRA
during fen<lldopam infusion, was more pronounced in the presence of lithium. The
fact that lithium did not influence the natriuresis during fenoldopam infusion, whereas
it did during gludopa administration might be lithium-dose related, or be explained by
a non-DAl-receptor mediated mechanism. In our study 300 mg lithium was used,
while in the gludopa study 750 mg lithium was used. Thus, although we cannot exclude
a dose related effect of lithium, our results do not substantiate an interaction of
lithium with renal tubular dopamine r€ceptors.
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Chapter 5 describes the acute renal and neurohumoral effects of 100 mg ibopamine
in patients with severe congestive heart failure. From studies, performed in the
seventies, we can learn that the renal effects of dopamine are more pronounced in
patients with congestive heart failure, compared to normals. For this reason we
performed this study, bearing in mind the results as described in chapter 3. All
patients used ACE-inhibitors, digoxin and diuretics. In this group of patients, an
increase of both GFR and renal blood flow was observed after the administration of
ibopamine. The filtration fraction, which was markedly increased even despite the use
of ACE-inhibitors, remained unchanged. No changes in blood pressure, heart rate,
PRA and aldosterone were observed. A possible effect on norepinephrine could not
be fully evaluated, due to a sampling error in some patients. The sodium excretion was
very low in these patients, and ibopamine did not induce any clinically significant
increase of the natriuresis. Probably the increase of GFR and renal blood flow is the
result of both a rise in cardiac output and a systemic and renal vasodilation. Although
we realize that this study was not controlled, we cnnclude that the renal hemodynamic
results suggest that the disappointing effects observed in normal volunteers, should not
be extrapolated to patients with congestive heart failure.
Another example of the different effects of dopamine receptor stimulation in
healthy subjects versus patients with congestive heart failure is provided by the
reported results of ibopamine on plasma norepinephrine. According to the literature
ibopamine lowers plasma norepinephrine in patients with congestive heart failure. This
is probably due to presynaptic DA2-receptor stimulation and additionally, this may be
the consequence of an improved hemodynamic situation of the patient. ln our study,
described in chapter 3, we observed no changes in plasma norepinephrine caused by
ibopamine in healthy subjects. Since we know from the literature that patients with
heart failure have an increased sympathetic drive, and in our healthy volunteers this
drive was reduced to a minimum, we hypothesized that the DA2-receptor effect of
ibopamine would only be apparent during sympathetic stimulation. In chapter 6 the
effects of ibopamine on exercise-induced increases of catecholamines in healthy
subjects are described. Maximal oxygen consumption (VOrmax) was determined using
a bicycle ergometric test. Subsequently, on two separate occasions, plasma catecholam-
ines were determined, after placebo or ibopamine. A graded exercise test was per-
formed up to 90qo of the predetermined VO2max level. As expected a rise of systolic-
and mean blood pressure, heart rate, norepinephrine and epinephrine level, with a fall
in diastolic blood pressure was found. No differences for blood pressure, heart rate
and epinephrine between the placebo- and ibopamine study day were found. Howev-
er, the rise of norepinephrine was significantly blunted by ibopamine, compared with
placebo, in accordance with our hypothesis.
The development of dopamine agonists is ongoing, with special attention to its oral
availability. The recent availability of SIM2055 for clinical studies is an example of
this progress. The presented data suggest that for chronic treatment, as in hyperten-
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advantageous. Data from in vitro studies as well as clinical studies suggest an interac-
tion of DA1- and DA2-receptors. Therefore studies comparing unique DAl- and
simultaneous DA1- & DA2-receptor stimulation are required. Furthermore, DA-
receptor mediated effects might be dependent on the salt-loading of the subject.
The field of research on dopamine receptors and dopaminergic drugs is challenging,
the dopamine-receptor-mediated effects are promising for clinical applications.
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